. equal contribution.
Results
In all, 727 men were enrolled between August 2007 and October 2015 (412 tE2, 315 LHRHa) with QoL questionnaires completed at both baseline and 6 months. Baseline clinical characteristics were similar between arms: median (interquartile range) age of 74 (68-79) years and PSA level of 44 ) ng/mL, and 40% (294/727) had metastatic disease. At 6 months, patients on tE2 reported higher global QoL than those on LHRHa (mean difference +4.2, 95% confidence interval 1.2-7.1; P = 0.006), less fatigue, and improved physical function. Men in the tE2 arm were less likely to experience hot flushes (8% vs 46%), and report a lack of sexual interest (59% vs 74%) and sexual activity, but had higher rates of significant gynaecomastia (37% vs 5%). The higher incidence of hot flushes among LHRHa patients appear to account for both the reduced global QoL and increased fatigue in the LHRHa arm compared to the tE2 arm.
Introduction
Prostate cancer is the most frequent cancer diagnosis in men in the developed world and responsible for 11 000 deaths per year in the UK and 26 000 in the USA [1, 2] . Prostate cancer cell growth is driven by androgen signalling, and androgen-deprivation therapy (ADT) forms a cornerstone of treatment. Evidence supports the use of ADT in conjunction with radiotherapy in localised [3, 4] and locally-advanced disease [5, 6] , and as first-line therapy in the metastatic setting [7] .
ADT, usually achieved using LHRH agonists (LHRHa) in contemporary practice, is associated with numerous sideeffects [8, 9] . Specifically, these include declining bone health [10, 11] , weight gain and metabolic syndrome [12] , sexual dysfunction [13] [14] [15] , hot flushes [16, 17] , mental and cognitive decline [18] [19] [20] [21] [22] , and physical deterioration and fatigue [23] [24] [25] [26] . LHRHa increase the risk of depression in men with prostate cancer [14] , reportedly driven by the loss of sexual function [27] . Recent data suggest an increased risk of subsequent Alzheimer's disease [28] . An association with increased cardiac events is described but remains controversial [29] . Whereas a number of interventions have been shown to ameliorate the toxicities of LHRHa to a greater or lesser extent [8] , further efforts are required to maintain the highest possible quality of life (QoL) for these patients.
PATCH (Prostate Adenocarcinoma: TransCutaneous Hormones, MRC PR09) is an ongoing randomised controlled trial comparing transdermal oestradiol (tE2) delivered via transcutaneous patches vs LHRHa in men with advanced prostate cancer. LHRHa act through the hypothalamic-pituitary axis to suppress testosterone production by the testes. Endogenous E2 in men is derived from testosterone through aromatase. Thus, it is also suppressed by, and consequently contributes to, the toxicity profile of LHRHa [9] . Exogenous administration of E2 inhibits the hypothalamic-pituitary axis (thereby suppressing testosterone) as well but maintains E2 levels and hence mitigates some of the toxicity of LHRHa. Administration of exogenous E2 via oral or i.v. routes is associated with risk of thrombosis and adverse cardiovascular events [30] . However, tE2 avoids the hepatic first-pass effects mediating these risks, as supported by previous results from PATCH (254 patients) showing similar rates of cardiovascular events in both tE2 and LHRHa arms after a median follow-up of 19 months [31] . Among this initial cohort, castration rates were similar in both arms.
In the present report, we compare QoL outcomes at 6 months from randomisation between the two hormonal treatments, based on data available from~700 patients.
Patients and Methods
The study design for the PATCH trial has previously been described [31] . Briefly, patients from participating UK centres were eligible for recruitment if they had locally advanced or metastatic prostate cancer, and a treatment plan for indefinite ADT in the metastatic setting or ≥3 years for locally advanced disease. National regulatory and ethics committees approved the protocol, and participating hospitals obtained the appropriate local approvals. Participants provided written informed consent.
Men were randomly allocated (in a 2:1 ratio before February 2011 and then 1:1) to receive tE2 or LHRHa (open-label). This was done centrally according to a computer-based minimisation algorithm with a random element (80%), balanced for the following factors: disease stage, age, smoking status, personal or family history of heart disease, which LHRHa agent was to be used, PSA level, intent to give radical radiotherapy, and centre.
Patients in the tE2 arm received, after a dose regimen change in August 2007 [32] , four FemSeven patches (oestradiol 100 lg/24 h), which were self-administered and changed twice weekly during the first 4 weeks. This was reduced to three patches changed twice weekly, provided testosterone levels were <1.7 nmol/L. LHRHa was administered as per local practice.
QoL Data Collection
Patients received a specific patient information sheet for the QoL study and provided separate consent to participate in this component of the study. QoL information was collected on paper questionnaires using the European Organisation for Research and Treatment of Cancer quality of life questionnaire 30-item core (EORTC QLQ-C30) and the prostate-specific module QLQ-PR25. These were selfcompleted by participants, who were instructed to record responses without discussion with site staff, friends or relatives. Data were collected before randomisation, then at 4, 8 and 12 weeks, and subsequently every 3 months up to 2 years after randomisation. The QLQ-C30 includes a range of domains that are either multi-item scales or single-item measures: a global health status/QoL scale, five function scales (physical, role, emotional, cognitive, and social), three symptom scales (fatigue, pain, and nausea and vomiting), and six single items (dyspnoea, insomnia, appetite loss, constipation, diarrhoea, and financial difficulties). QLQ-PR25 contains 25 items designed to assess QoL in patients with prostate cancer, including urinary, bowel and sexual symptoms and functioning, and hormone-related symptoms. 
Statistical Analysis
For each multi-item QoL domain (e.g. global QoL), a summary score was derived according to the EORTC QLQ-C30 scoring manual [33] , with a range of 0-100. For example, the summary global QoL score is a standardised average of the patients' scores from the questions 'How would you rate your overall health during the past week?' and 'How would you rate your overall quality of life?'. These scores were considered as continuous variables. A higher score corresponds to improved outcomes for global QoL and function scales, but indicates more symptoms (hence poorer outcomes) for symptoms scales. Single-item domains (e.g. sexual interest) were analysed based on reported responses on the questionnaires ('not at all', 'a little', 'quite a bit', or 'very much').
The primary outcome was global QoL score at 6 months, as differences in hormone-related symptoms potentially impacting on QoL were expected to be apparent by then [17, 20, 25, 26, 31] . The following domains were secondary outcomes: sexual interest, sexual activity, whether feeling less masculine as result of illness or treatment, cognitive functioning, physical functioning, fatigue, and selected hormone-related symptoms of hot flushes, gynaecomastia, and weight gain. Gynaecomastia was reported as sore or enlarged nipples or breasts.
Patients were considered to have baseline QoL data, if they completed their first QoL questionnaire either by the date of randomisation or 1 week after, but before starting trial treatment. Information on QoL outcomes at 6 months was based on the questionnaire completed nearest to this time point, within a AE 3-month window.
Multi-item QoL domains at 6 months were compared between randomised arms using Tobit regression models (to account for scores being bounded by 0 and 100) [34] , adjusting for baseline score. Single-item domains were categorised according to pre-defined binary outcomes for comparison between arms (for ease of clinical interpretation); for example, hot flushes were analysed as 'quite a bit'/'very much' vs 'not at all'/'a little'. These were compared between arms using logistic regression models, adjusting for baseline response.
All models were further adjusted for the following predefined baseline factors: age, calendar year (partly to account for the change in allocation ratio), smoking status, stage of disease (M0/M1), and whether patient was newly diagnosed or relapsing. All comparisons between arms were based on the original allocated treatment, and included patients randomised after the change in patch dose regimen [32] who had data on the relevant QoL domains at both baseline and 6 months. A significance level of 0.05 was chosen a priori, without adjustment for multiple statistical testing. Additional exploratory analyses were undertaken to investigate associations between global QoL and other domains.
Statistical analyses were performed using Stata version 14 (Stata Corporation, College Station, TX, USA).
Results
Between 14 August 2007 and 5 October 2015, 875 men were recruited under the revised patch dose regime, 480 allocated to tE2 and 395 to LHRHa. Within the tE2 arm, 468 patients enrolled on the QoL sub-study, of whom 412 (86% of 480) completed QoL questionnaires at both baseline and 6 months. For the LHRHa group, 385 participated in the QoL substudy, with 315 (80% of 395) having both baseline and 6-month QoL data available (Fig. 1 ). Baseline clinical characteristics were similar between arms for the 727 patients included in the 6-month QoL analyses (Table 1 ). The overall median (interquartile range) age was 74 (68-79) years and PSA level was 44 (19-119) ng/mL, and 40% (294/727) had metastatic disease. There were no differences in baseline global QoL by age or testosterone level, but men with T4 tumours had worse global QoL compared with other T-stages, and patients with metastatic disease had worse baseline QoL than M0 patients.
Rates of castration were equivalent between the LHRHa and tE2 arms at both 3 and 6 months; the proportion of patients with testosterone concentrations ≤1.7 nmol/L was 93.6% for LHRHa and 93.7% for tE2 at 3 months, and 89.8% and 92.2% at 6 months, respectively. At 6 months, global QoL declined from baseline in both arms (Table 2 ), but to a lesser extent in the tE2 patients (mean change À2.8) compared to those on LHRHa (À5.0). The estimated mean difference in 6-month global QoL between arms was +4.2 (95% CI 1.2-7.1; P = 0.006) in favour of tE2. There was no evidence that the treatment effect on global QoL at 6 months differed by age (≤70 vs >70 years; test for interaction P = 0.56).
In addition, there was less decline in physical function among tE2 patients (mean change À2.8 vs À5.7), with a mean difference in 6-month score of +5.8 (95% CI 2.8-8.8; P < 0.001) between arms. In addition, tE2 patients had less fatigue at 6 months, mean difference between arms À4.3 (95% CI À8.1 to À0.6; P = 0.02) favouring the patches. However, there was no difference in reported decline in cognitive function between arms.
Analysis of specific domains linked with testosterone suppression (Table 3) showed that tE2 patients were less likely than LHRHa patients to report having no interest in sex [59% vs 74%; odds ratio (OR) 0.42, 95% CI 0.28-0.62; P < 0.001)] and being 'not at all' sexually active (78% vs 87%; OR 0.51, 95% CI 0.32-0.82; P = 0.005). Interestingly, there was weak evidence that the negative effect of LHRHa compared to tE2 on interest in sex was more pronounced in patients aged ≤70 years than those >70 years (t-test for interaction P = 0.06).
The likelihood of experiencing 'quite a bit' or 'very much' hot flushes was significantly lower in the tE2 group (8% vs 46%; OR 0.10, 95% CI 0.07-0.16; P < 0.001). However, as expected, patients in the tE2 arm were much more likely to report 'quite a bit' or 'very much' gynaecomastia than those receiving LHRHa (37% vs 5%; OR 12.70, 95% CI 7.14-22.60; P < 0.001). There was no difference between arms in patients who reported feeling 'quite a bit' or 'very much less' masculine (as a result of their illness or treatment) or experiencing 'quite a bit' or 'very much' weight gain.
An association between hot flushes and deterioration in global QoL was seen in both arms at 6 months, with patients who experienced more severe symptoms reporting lower scores ( As overall survival is a co-primary outcome measure in the ongoing trial, the number of patients who have died before completing 6-month QoL questionnaire is not provided.
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© 2016 The Authors BJU International © 2016 BJU International 6 months (Table 5 , P = 0.004), although the adverse effect was only seen in patients reporting 'very much' gynaecomastia (corresponding to 8% of the group with data available). Other QoL domains associated with lower global QoL score were: poorer cognitive and physical function, increased fatigue, weight gain, and feeling less masculine (data not shown).
After accounting for hot flushes, there was little difference in the 6-month global QoL score between arms (estimated mean difference comparing tE2 vs LHRHa À0.4, 95% CI À3.8 to 3.0; P = 0.80). In comparison, the difference between arms remained after other QoL domains were individually adjusted for (data not shown). This suggests a significant component of the effect of treatment arm on global QoL could potentially be attributable to the higher incidence of hot flushes in LHRHa patients.
In addition, there was an association between severity of hot flushes and fatigue at 6 months in both arms (data not shown), which may potentially account for the increased fatigue in the LHRHa vs tE2 arm; after adjusting for hot flushes, there was little difference in the 6-month fatigue score between arms (mean difference comparing tE2 vs LHRHa 0.0, 95% CI À4.3 to 4.4; P = 0.98). Further post hoc analyses showed a relationship between hot flushes and sleep disturbance within both arms; 72% (124/172) of patients reporting 'quite a bit' or 'very much' hot flushes had trouble sleeping compared to 43% (232/534) of those with 'not at all' or 'a little' hot flushes (P < 0.001, with similar results by arm).
Patients experiencing gynaecomastia were more likely to report feeling less masculine at 6 months, with 24% (36/148) of men who reported 'quite a bit' or 'very much' gynaecomastia feeling 'quite a bit' or 'very much' less masculine compared to 7% (17/247) of those reporting 'not at all' or 'a little' gynaecomastia (P < 0.001). The protocol explicitly allowed prophylactic breast bud radiotherapy and 5% of patients on tE2 received this treatment as opposed to no patients on LHRHa. Two patients underwent surgical treatment for gynaecomastia who were both on tE2, corresponding to 0.4% (2/480) of the overall tE2 arm cohort enrolled to date.
Discussion
In the present study, we found better overall QoL after 6 months of ADT with tE2 compared to LHRHa, as well as less fatigue and improved physical function. While the magnitude of the QoL effects was modest [35] , some additional differences are important to note. Men treated with LHRHa were more likely to report lack of sexual interest (74% vs 59%) and being not sexually active (87% vs 78%) [20] . In addition, tE2 patients had lower rates of hot flushes but more gynaecomastia, consistent with earlier findings from the trial [31] .
Significant hot flushes were reported by 8% of men on tE2 compared to 44% of those on LHRHa. Interestingly, there was a suggestion that hot flushes mediated the treatment effect on global QoL, potentially accounting for both the reduced global QoL and increased fatigue in the LHRHa compared to tE2 arm. Conversely, 37% men on tE2 reported significant gynaecomastia compared with 5% on LHRHa, although gynaecomastia was only seen to adversely affect global QoL if the patient reported 'very much' symptoms (which corresponded to <10% of the tE2 cohort). It is noteworthy that men may vary significantly in how bothersome gynaecomastia is on an individual basis [36] . In addition, data from the main PATCH trial suggest no association between E2 levels and clinical gynaecomastia (data not shown). LHRHa therapy can severely impact on physical well-being and other QoL outcomes [14] [15] [16] . Hot flushes, reported by 40-80% of men on LHRHa [17, 37, 38] , are linked to sleep disturbance and psychological distress [16, 38] . In our present study, patients with hot flushes had more trouble sleeping, which may account for the effect of hot flushes on increased fatigue and reduced QoL. tE2 appeared to be effective in reducing the severity of hot flushes in men on ADT in a prior study, consistent with our present findings [39] . The adverse effects of LHRHa on sexual outcomes, which can have significant psychological impact on both patients and their partners, have also been well-documented [13] [14] [15] . Data from men castrated for reasons other than prostate cancer suggest exogenous oestrogen can help maintain sexual interest [40, 41] . Other potential benefits of tE2 reported include protective effects on cognition [42] , although we did not find a difference in cognitive function between arms within our present study, possibly because short-term outcomes were analysed and/or limitations of the questionnaires used for assessing the cognitive domain.
Several strategies have been investigated in an attempt to mitigate the adverse effects LHRHa therapy [8] . Randomised trials have shown some benefit of medoxyprogesterone, venlafaxine and gabapentin in reducing hot flushes associated with LHRHa, and exercise may improve levels of fatigue and overall QoL [43] [44] [45] . Agents which can potentially preserve bone health during treatment with LHRHa include bisphosphonates, denosumab or toremifine [8] . Importantly, however, data from PATCH recently showed that patients on tE2 avoid the loss in bone mineral density seen with LHRHa administration [46] . The data presented here suggest tE2 as an alternative to LHRHa might limit the requirement for additional treatments to allay the side-effects of LHRHa over and above bone health. Alternatively a low dose of tE2 in addition to LHRHa could be investigated in the future as a treatment for bothersome hot flushes.
Alternatively, an intermittent approach to ADT has been assessed for clinical efficacy and potential QoL benefits. In the non-metastatic setting, intermittent ADT appears not to be inferior to continuous therapy in terms of overall survival, with some potential benefits as regards hot flushes, libido and possibly fatigue, but not global health [47] . However, a randomised trial by Hussain et al. [48] including 1535 men with metastatic prostate cancer failed to show non-inferiority for intermittent ADT based on overall survival. Although small improvements were initially seen for sexual function and mental health, older men assigned to intermittent ADT had no apparent reduction in bone, endocrine, or cognitive events and experienced an increased incidence of ischaemic and thrombotic events [49] .
It is increasingly apparent across a number of QoL domains that there are important differences in the unintended consequences of ADT depending upon the method chosen to achieve castrate levels of testosterone [50, 51] . Here, we have shown that at 6 months of treatment, tE2 improves patients' QoL in a number of domains compared to LHRHa, i.e. fewer hot flushes, less fatigue, improved physical functioning, sexual interest and sexual activity, but at a cost of increased incidences of gynaecomastia. This can be viewed in addition to the beneficial effects on tE2 on bone mineral density previously reported within PATCH [46] , also noting the lack of any excess cardiovascular or thromboembolic effects from tE2 [31] . From our present data, hot flushes appear to potentially account for the increased fatigue and reduced global QoL among patients on LHRHa.
We acknowledge the relatively short-term outcomes assessed and presented here. However, ADT is often used for periods as short as 6 months when administered as neoadjuvant therapy along with radiotherapy to treat localised disease. As such, our present 6-month QoL data are clinically pertinent, given short-term neoadjuvant ADT has been shown to be associated with impaired QoL [52] . Further data from the ongoing trial will inform whether the differences between arms persist long term. Although it is premature to suggest a fundamental change in practice when it comes to starting patients on ADT, comprehensive analysis of comparative efficacy and toxicity within PATCH will allow men and their partners to optimise treatment choices. list of members). We also thank all previous and current members of the PATCH trial team including: Gordana Jovic who currently maintains the statistical database for the trial; Anna Bara for overseeing the practical running of the trial; Robin Carpenter for his assistance with the data management; *Estimated from Tobit regression models, adjusted for treatment arms, baseline global QoL score and other pre-defined baseline factors. There was no evidence that the effect of hot flushes on 6-month global QoL score differed by treatment arm (P for interaction = 0.20). 
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